
Hybridoma Medium
Hyber series serum-free medium for hybridoma cells
Hyber hybridoma cell media, developed by Shanghai BioEngine Sci-Tech Co., Ltd., is a serum-free medium that supports the growth of hybridoma cells and efficient antibody expression. It is suitable for laboratory to large-scale suspension culture, and ensures the safety and reliability of the production process.Description
Performance
Features
A completely serum-free culture system
No ingredients of animal-derived, genetically modified plant origin or raw materials with BSE origin
No antibiotics, organic solvents, or preservatives
Containing hydrolysate, L-glutamine, hypoxanthine, and thymine nucleoside
Supporting high-density suspension culture and protein expression of hybridoma cells
Advantages
Animal-derived component-free; TSE/BSE statement available on demand
Distinctive culture results proven in numerous studies
Optional powder media for use in large-scale manufacturing with easy preparation procedures
Powder media capable of a single batch size of 100,000 L
Excellent inter-batch consistency (CPK*>1.33)
EU certified ISO13485:2016 QMS and MDSAP (FDA), all data are traceable
*CPK: Process Capability Index. CPK>1.33 indicates good process control and small inter-batch difference of products.

Order Information
Basal Medium
Feed Medium
|
Application |
Product Name |
Cat. No. |
Size |
Form |
Product Instruction (pdf) |
|
|
Support high-density suspension culture and efficient expression of hybridoma cells |
Hyber-B100S Hybridoma Cell Serum-free Medium | EXP0111205 |
200 L |
Powder |
||
| EXP0111202 |
10 L |
Powder |
||||
| Hyber-B100S Additive | EXP0120901 |
100 ml |
Liquid |
|||
| EXP0111902 | 10ml | Liquid |
|
Application |
Application |
Cat. No. |
Size |
Form |
Product Instruction (pdf) |
|
|
Support high-density suspension culture and efficient expression of hybridoma cells |
Hyber-F100S Hybridoma Cell Serum-free Feed Medium | EXP0111303 |
30 L |
Powder |
||
| EXP0120302 |
2 L |
Powder |
Performance
For Vaccines
Suspension acclimation of adherent hybridoma cells
The use of Hyber-B100S with gradual reduction of the serum content during continued acclimation of hybridoma cells allowed transition of serum-dependent adherent cells into serum-free suspension cells. Suspension cells were individually dispersed with uniform cell size and showed a stable growth rate during the passages.

Batch culture of suspension hybridoma cells
In Hyber-B100 serum-free medium, batch culture of hybridoma cells was performed, achieving a maximum viable cell density (VCD) of 8×106 cells/m. Additionally, when combined with feed medium (Hyber-F100S) in fed batch culture, better results were obtained.

Fed-batch usage strategy
Instruction for using hyber-F100S hybridoma cell feed medium:

Documents
Hybridoma Medium
DownloadFAQ
Q1:What is the most popular cell culture media?
Q2:What is the hybridoma technology in antibody production?
Q3:Why is DMEM medium red?
Q4:What is the best media for T cells?
Q5:Why use DMEM for cell culture?
Q6:What are the differences between 293 cells and CHO cells in protein production?
Q7:How can serum-free cell culture media be optimized?
Previous
No InformationNext
No InformationHot Tags: hybridoma medium, China hybridoma medium manufacturers, suppliers, factory
Antibodies
In fed-batch process, CHO cells cultured in Eden CD CHO media demonstrate higher viable cell density (VCD) and protein production than competitors. On average, the antibody titers of various CHO cell lines cultured in Eden CD CHO media ranged from 2 to 11 g/L.

In the pulse perfusion process, CHO cells cultured in Eden CD CHO media demonstrated superior performance than competitive global brands. When VVD=1.0, volumetric productivity (Vp) can reach up to 2.2 g/L/day, and the cumulative product expression in 14 days can reach 19 g/L, 55% higher than global brand B. When VVD=2.0, Vp can reach up to 3.3g/L/day, and the cumulative product expression in 14 days can reach 25 g/L.

Brochures
| CHO Cell Medium |
FAQ
Q1: What is the packaging for BioEngine's powder media?
Q2: Can we seal the bag if there is leftover powdered medium?
Q3: What is the shelf life of BioEngine's Eden series CHO cell culture media, and how do you verify the expiration date?
Q4: Does BioEngine offer any regulators or additives for modulating antibody glycosylation?
Q5: Does BioEngine's CHO cell culture media contain hydrolysates, insulin, cytokines, or other components?
Q6: What are CHO media?
Q7: What are the differences between DMEM and RPMI?
1. Nutrient composition: DMEM (Dulbecco's Modified Eagle's Medium) and RPMI (Roswell Park Memorial Institute) have different nutrient compositions. DMEM contains higher levels of glucose, amino acids, vitamins, and sodium pyruvate, while RPMI has a lower glucose concentration and a different amino acid and vitamin composition.
2. pH: DMEM has a higher pH (7.4-7.6) compared to RPMI (7.2-7.4).
3. Usage: DMEM is a more general-purpose medium and can be used for a wide range of cell types, including adherent and non-adherent cells, while RPMI is typically used for the culture of immune cells such as lymphocytes and hybridomas.
4. Serum requirement: RPMI is often used with lower serum concentrations (e.g. 5-10%) than DMEM, which may require higher serum concentrations (e.g. 10-20%).
Overall, the choice between DMEM and RPMI depends on the specific cell type being cultured and the experimental conditions.
Q8: What is a fed-batch culture?
The goal of a fed-batch culture is to maximize cell growth and productivity while maintaining a stable culture environment. By controlling the rate and timing of nutrient addition, the culture can be kept in a state of controlled growth, avoiding the depletion of nutrients and accumulation of waste products that can limit growth and product formation in batch cultures. Additionally, the use of a fed-batch culture can allow for the accumulation of high cell densities and the optimization of production conditions, leading to higher yields and greater efficiency in bioprocesses.
Q9: What are the advantages of suspension cell cultures?
1. Scalability: Suspension cell cultures can be easily scaled up to produce large quantities of cells. This makes them particularly useful for biomanufacturing and the production of recombinant proteins.
2. Flexibility: Suspension cultures can be adapted to a wide range of culture conditions, such as pH, temperature, and nutrient availability. This allows for the optimization of cell growth and productivity.
3. Homogeneity: Suspension cultures provide a more homogeneous population of cells than adherent cultures, where cells may exhibit varying degrees of differentiation and proliferation.
4. Reduced risk of contamination: Suspension cultures are less prone to contamination by bacteria or fungi than adherent cultures, as there are no surfaces for microorganisms to adhere to.
5. Ease of harvesting: Cells in suspension culture can be easily harvested using centrifugation, filtration, or other methods. This simplifies downstream processing and reduces the risk of damage to the cells.
Overall, suspension cell culture offers several advantages over other types of cell culture, particularly in the context of large-scale biomanufacturing and the production of recombinant proteins.
Q10: What is gene therapy?
●Replacing a disease-causing gene with a healthy copy of the gene.
●Inactivating or deleting a disease-causing gene.
●Introducing a new or modified gene to help fight disease.
Gene therapy is a promising and innovative field of medicine that has potential applications for many diseases, such as cancer, genetic disorders, infectious diseases, and autoimmune diseases 23. However, gene therapy also faces many challenges and risks, such as safety, efficacy, ethical issues, and regulatory hurdles.
Gene therapy usually be delivered to the cells by virus vector, such as AAV, Adv and RV. BioEngine provides vigor series insect cell media for large scale AAV production."
Q11: Does BioEngine provides serum products, like FBS?
Previous
No InformationNext
CD Hybridoma MediumSend Inquiry
Provide high quality culture media for research institutions, biopharmaceutical companies and clinical trial institutions, etc.
I agree to receive other communications from BioEngine which may contain technical or marketing information from this organization. You can unsubscribe from these communications at any time.
By submitting this form, you are agreeing to the terms and conditions of our Privacy Policy
You Might Also Like







